Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy. Electronic address: francesco.passamonti@ospedale.varese.it.
Francesco
F
Passamonti
D002986:Clinical Trials as Topic; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D053614:Janus Kinase 2